X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the clinical trial agreement, Brigham and Women’s Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101, a Complete Consortia microbiome therapeutic, in ulcerative colitis.
Lead Product(s): CP101
Therapeutic Area: Gastroenterology Product Name: CP101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brigham and Women’s Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 18, 2023
Details:
CP101 is an investigational, orally administered microbiome therapeutic designed to prevent recurrent C. diff and enable early intervention in the management of C. diff.
Lead Product(s): CP101
Therapeutic Area: Infections and Infectious Diseases Product Name: CP101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
CP101 is an investigational microbiome therapeutic designed to deliver a diverse microbial community in a one-time oral administration, without the need for bowel preparation.
Lead Product(s): CP101
Therapeutic Area: Infections and Infectious Diseases Product Name: CP101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
FIN-524 and FIN-525 are investigational, orally administered targeted consortia product candidates composed of both spore-forming and non-spore-forming bacterial strains selected for the treatment of ulcerative colitis and Crohn’s disease, respectively.
Lead Product(s): FIN-524
Therapeutic Area: Gastroenterology Product Name: FIN-524
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
CP101 is the Company’s investigational orally administered microbiome therapeutic which is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI).
Lead Product(s): CP101
Therapeutic Area: Infections and Infectious Diseases Product Name: CP101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Finch was able to continue dosing patients in its then-ongoing PRISM-EXT Phase 2 open-label trial of CP101 in recurrent CDI as all of the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.
Lead Product(s): CP101
Therapeutic Area: Infections and Infectious Diseases Product Name: CP101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Two New U.S. Patents Granted for FIN-211, the first patent covers key technologies involved in addressing ASD and GI symptoms and, the second patent covers encapsulated compositions and methods of manufacturing such compositions.
Lead Product(s): FIN-211
Therapeutic Area: Psychiatry/Psychology Product Name: FIN-211
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
CP101 demonstrated efficacy through week 24, with 73.5% of participants in the CP101 arm (n=102) experiencing a sustained clinical cure (defined as absence of CDI recurrence) through week 24 versus 59.4% in the placebo arm (n=96) (p=0.0347).
Lead Product(s): CP101
Therapeutic Area: Infections and Infectious Diseases Product Name: CP101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
Takeda will assume primary development responsibility for the program, now known as TAK-524. The transition will enable Takeda to leverage its expertise in inflammatory bowel disease (IBD) throughout the clinical development of FIN-524/TAK-524.
Lead Product(s): FIN-524
Therapeutic Area: Gastroenterology Product Name: TAK-524
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2021
Details:
Late-breaker oral presentations expand on previously announced positive topline data showing that CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection compared to placebo.
Lead Product(s): CP101
Therapeutic Area: Infections and Infectious Diseases Product Name: CP101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
